Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Line item | Neolabi | Mrcheveli-Batumi | Jandatsvis Saertashoris… | Kromos Pharma Sakartvelo | In Taim Diagnostik Geor… |
|---|---|---|---|---|---|
| Total Revenue | 2,347 | 2,310 | 2,161 | 2,110 | — |
| Total COGS | -606 | 0 | -68 | 0 | — |
| Gross Profit | 1,742 | 2,310 | 2,093 | 2,110 | — |
| Gross Margin | 74.2% | 100.0% | 96.9% | 100.0% | — |
| Total Operating Expenses | -2,374 | -1,207 | -3,092 | -2,052 | — |
| EBITDA | -632 | 1,103 | -999 | 59 | — |
| EBITDA Margin | -26.9% | 47.8% | -46.2% | 2.8% | — |
| Total D&A | -470 | -77 | -29 | -10 | — |
| EBIT / Operating Income | -1,102 | 1,026 | -1,028 | 48 | — |
| Total Interest Income | 4 | — | — | — | — |
| Total Other Income | 55 | — | 84 | — | — |
| Profit Before Tax | -1,043 | 1,024 | -944 | 48 | — |
| Total Income Tax | 0 | 0 | 0 | 0 | — |
| Net Profit / (Loss) | -643 | 1,024 | -944 | 24 | — |
| Net Margin | -27.4% | 44.3% | -43.7% | 1.1% | — |
| Total Interest Expense | — | -2 | — | — | — |
Not every picked company reports every selected year — FY2024: no filing for In Taim Diagnostik Geor…. Those cells are left blank (no filing), not zero.
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Mrcheveli-Batumi | Healthcare Services | 47.8% | 97th pct | 268 |
| Kromos Pharma Sakartvelo | Healthcare Services | 2.8% | 28th pct | 268 |
| Neolabi | Healthcare Services | -26.9% | 6th pct | 268 |
| Jandatsvis Saertashoris… | Healthcare Services | -46.2% | 5th pct | 268 |
| In Taim Diagnostik Geor… | Healthcare Services | — | no FY data | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.